Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A compound of formula (I):



formula (I)

wherein **A** is ~~6-membered heteroaryl containing a nitrogen atom and optionally containing one or two further nitrogen atoms~~ a group of formula (a) or (b):



(a) (b)

where * is the point of attachment to the X group of formula (I) and ** is the point of attachment to the Y group of formula (I);

X is O, S, S(O), $S(O)_2$ or NR^{14};

m is 0, 1, 2, 3 or 4;

Y is a group selected from O, NR^5CO, $CONR^5$, $CR^6R^7CONR^5$ and $CR^6R^7NR^5$;

Z is a group selected from $-NR^1R^2$~~, phosphonooxy, C_{3-6}cycloalkyl which C_{3-6}cycloalkyl is substituted by phosphonooxy or C_{1-4}alkyl substituted by phosphonooxy, and a 4- to 7-membered ring linked via a carbon atom containing a nitrogen atom and optionally containing a further nitrogen atom, which ring may be saturated, unsaturated or partially saturated which ring is substituted on carbon or nitrogen by phosphonooxy or C_{1-4}alkyl (substituted by phosphonooxy) and which ring is optionally further substituted on carbon or nitrogen by 1, 2 or 3 halo or C_{1-4}alkyl groups~~;

R^1 is a group selected from $-COR^8$, $-CONR^8R^9$ and C_{1-6}alkyl which C_{1-6}alkyl is substituted by phosphonooxy and optionally further substituted by 1 or 2 halo or methoxy groups;

R^2 is a group selected from hydrogen, $-COR^{10}$, $-CONR^{10}R^{11}$ and C_{1-6}alkyl which C_{1-6}alkyl is optionally substituted by 1, 2 or 3 halo or C_{1-4}alkoxy groups, $-S(O)_pR^{11}$ (where p is 0, 1 or 2) or phosphonooxy, or R^2 is a group selected from C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-6}cycloalkyl and C_{3-6}cycloalkylC_{1-4}alkyl;

~~or **R^1** and **R^2** together with the nitrogen to which they are attached form a 4- to 7- membered ring optionally containing a further nitrogen atom which ring may be saturated, unsaturated or partially saturated which ring is substituted on carbon or nitrogen by a group selected from phosphonooxy and C_{1-4}alkyl substituted by phosphonooxy or $-NR^8R^9$, and which ring is optionally further substituted on carbon or nitrogen by 1, 2 or 3 halo or C_{1-4}alkyl groups;~~

R^3 is a group selected from hydrogen, halo, cyano, nitro, C_{1-6}alkoxy, C_{1-6}alkyl, $-OR^{12}$, $-CHR^{12}R^{13}$, $-OC(O)R^{12}$, $-C(O)R^{12}$, $-NR^{12}C(O)R^{13}$, $-C(O)NR^{12}R^{13}$, $-NR^{12}SO_2R^{13}$ and $-NR^{12}R^{13}$;

R^4 is hydrogen or a group selected from C_{1-4}alkyl, heteroaryl, heteroarylC_{1-4}alkyl, aryl and arylC_{1-4}alkyl which group is optionally substituted by 1, 2 or 3 substituents selected from halo, methyl, ethyl, cyclopropyl and ethynyl;

R^5 is a group selected from hydrogen, C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, C_{3-6}cycloalkyl and C_{3-6}cycloalkylC_{1-4}alkyl;

R^6 and **R^7** are independently selected from hydrogen, halo, C_{1-4}alkyl, C_{3-6}cycloalkyl, hydroxy and C_{1-4}alkoxy;

R^8 is C_{1-4}alkyl substituted by phosphonooxy and optionally further substituted by 1 or 2 halo or methoxy groups;

R^9 is selected from hydrogen and C_{1-4}alkyl;

R^{10} is selected from hydrogen and C_{1-4}alkyl which C_{1-4}alkyl is optionally substituted by halo, C_{1-4}alkoxy, $S(O)_q$ (where q is 0, 1 or 2) or phosphonooxy;

R^{11}, **R^{12}**, **R^{13}** and **R^{14}** are independently selected from hydrogen, C_{1-4}alkyl and heterocyclyl;

or a pharmaceutically acceptable salt thereof.

2. (cancelled)

3. (currently amended) A compound according to claim 2 wherein A is a group of formula (b) ~~or (d)~~ as defined in claim [[2]] 1; or a pharmaceutically acceptable salt thereof.

4. (previously amended) A compound according to claim 1 wherein X is NH; or a pharmaceutically acceptable salt thereof.

5. (canceled)

6. (previously amended) A compound according to claim 1 wherein R^1 is C_{1-5}alkyl substituted by phosphonooxy and R^2 is hydrogen, C_{1-5}alkyl, C_{2-4}alkynyl or C_{3-6}cycloalkyl; or a pharmaceutically acceptable salt thereof.

7. (cancelled)

8. (previously amended) A compound according to claim 1 wherein R^3 is methoxy or hydrogen; or a pharmaceutically acceptable salt thereof.

9. (previously amended) A compound according to claim 1 wherein R^4 is phenyl or benzyl optionally substituted by 1 or 2 of fluoro or chloro; or a pharmaceutically acceptable salt thereof.

10. (currently amended) A compound selected from:
3-[(3-{[4-({6-[(3-chlorobenzyl)oxy]pyridin-3-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)amino]-3-methylbutyl dihydrogen phosphate;
3-[(3-{[4-({6-[(3-chlorobenzoyl)amino]pyridin-3-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)amino]-3-methylbutyl dihydrogen phosphate;
2-[(3-{[4-({6-[(3 chlorobenzoyl)amino]pyridin-3-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)(ethyl)amino]ethyl dihydrogen phosphate;
~~2-[1-(3-{[4-({6-[(3-chlorobenzoyl)amino]pyridin-3-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)piperidin-2-yl]ethyl dihydrogen phosphate;~~
~~[(2R)-1-(3-{[4-({6-[(3-chlorobenzoyl)amino]pyridin-3-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)pyrrolidin-2-yl]methyl dihydrogen phosphate;~~
~~2-[1-(3-{[4-({6-[(3-chlorobenzoyl)amino]pyridin-3-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)piperidin-4-yl]ethyl dihydrogen phosphate;~~
2-[ethyl(3-{[4-({6-[(3-fluorobenzoyl)amino]pyridin-3-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)amino]ethyl dihydrogen phosphate;
2-[(3-{[4-({6-[(3,4-difluorobenzoyl)amino]pyridin-3-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)(isopropyl)amino]ethyl dihydrogen phosphate;
~~(3-{[4-({6-[(3-chlorobenzoyl)amino]pyridin-3-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)piperidin-4-yl dihydrogen phosphate;~~

~~4-{[4-({6-[(3-chlorobenzoyl)amino]pyridin-3-yl}amino)-6-methoxyquinazolin-7-yl]oxy}butyl dihydrogen phosphate;~~

2-[(3-{[4-({6-[(3-chlorobenzoyl)amino]pyridin-3-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)(methyl)amino]ethyl dihydrogen phosphate;

~~[1-(3-{[4-({6-[(3-chlorobenzoyl)amino]pyridin-3-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)piperidin-2-yl]methyl dihydrogen phosphate;~~

2-[(5-{[4-({6-[(3-chlorobenzoyl)amino]pyridin-3-yl}amino)-6-methoxyquinazolin-7-yl]oxy}pentyl)(ethyl)amino]ethyl dihydrogen phosphate;

4-[(3-{[4-({6-[(3-chlorobenzoyl)amino]pyridin-3-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)(ethyl)amino]butyl dihydrogen phosphate;

2-[(3-{[4-({6-[(3-fluorobenzoyl)amino]pyridin-3-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)(methyl)amino]ethyl dihydrogen phosphate;

2-[(3-{[4-({6-[(3-chlorobenzoyl)amino]pyridin-3-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)(isobutyl)amino]ethyl dihydrogen phosphate;

2-[(3-{[4-({6-[(3-chlorobenzoyl)amino]pyridin-3-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)(cyclopropyl)amino]ethyl dihydrogen phosphate;

~~[1-(3-{[4-({6-[(3-chlorobenzoyl)amino]pyridin-3-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)piperidin-4-yl]methyl dihydrogen phosphate~~;

~~2-[4-(3-{[4-({6-[(3-chlorobenzoyl)amino]pyridin-3-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)piperazin-1-yl]ethyl dihydrogen phosphate~~;

~~[(2*S*)-1-(3-{[4-({6-[(3-chlorobenzoyl)amino]pyridin-3-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)pyrrolidin-2-yl]methyl dihydrogen phosphate~~;

2-[(3-{[4-({6-[(3-chlorobenzoyl)amino]pyridin-3-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)(cyclobutyl)amino]ethyl dihydrogen phosphate;

2-[(3-{[4-({6-[(3-chlorobenzoyl)amino]pyridin-3-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)(prop-2-yn-1-yl)amino]ethyl dihydrogen phosphate;

2-[(3-{[4-({2-[(3-chloro-4-fluorobenzoyl)amino]pyrimidin-5-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)(cyclohexyl)amino]ethyl dihydrogen phosphate;

2-[(3-{[4-({2-[(3-chloro-4-fluorobenzoyl)amino]pyrimidin-5-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)(ethyl)amino]ethyl dihydrogen phosphate;

~~3-{[4-({2-[(3-chlorobenzoyl)amino]pyrimidin-5-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl dihydrogen phosphate~~;

~~1-[3-({4-[(2-{[(3-chloro-4-fluorophenyl)amino]methyl}pyrimidin-5-yl)amino]-6-methoxyquinazolin-7-yl}oxy)propyl]piperidin-4-yl dihydrogen phosphate~~;

3-[(3-{[4-({2-[(3-chloro-4-fluorobenzyl)oxy]pyrimidin-5-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)amino]-3-methylbutyl dihydrogen phosphate;
2-[(3-{[4-({2-[(3-chlorobenzoyl)amino]pyrimidin-5-yl}amino)-6-methoxyquinazolin-7-yl]oxy}propyl)(2,2-dimethylpropyl)amino]ethyl dihydrogen phosphate;
~~[2-({[4-({2-[(3-chloro-4-fluorobenzoyl)amino]pyrimidin-5-yl}amino)-6-methoxyquinazolin-7-yl]oxy}methyl)cyclopropyl]methyl dihydrogen phosphate;~~ and
~~2-[4-({[4-({2-[(3-chloro-4-fluorobenzoyl)amino]pyrimidin-5-yl}amino)-6-methoxyquinazolin-7-yl]oxy}methyl)piperidin-1-yl]ethyl dihydrogen phosphate~~;
or a pharmaceutically acceptable salt thereof.

11. (previously amended) A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable diluent or carrier.

12.-15. (cancelled)

16. (withdrawn) A method of treating a human suffering from a disease in which the inhibition of one or more Aurora kinases is beneficial to the treatment, comprising the steps of administering to a person in need thereof a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

17. (withdrawn) A method of treating a human suffering from colorectal, breast, lung, prostate, pancreatic or bladder and renal cancer or leukemias or lymphomas, comprising the steps of administering to a person in need thereof a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

18. (currently amended) A process for the preparation of a compound of formula (I) claim 1 or a pharmaceutically acceptable salt thereof, which process comprises converting a compound of formula (II) into a compound of formula (I) by phosphorylation of an appropriate hydroxy group:



formula (II)

where A, X, m, Y, R^3 and R^4 are as defined for formula (I); and **Z'** is a group selected from -$NR^{1'}R^{2'}$, ~~hydroxy, C_{3-6}cycloalkyl which C_{3-6}cycloalkyl is substituted by hydroxy or C_{1-4}alkyl substituted by hydroxy, and a 4- to 7-membered ring linked via a carbon atom, containing a nitrogen atom and optionally containing a further nitrogen atom, which ring may be saturated, unsaturated or partially saturated and which ring is substituted on carbon or nitrogen by hydroxy or C_{1-4}alkyl substituted by hydroxy and which ring is optionally further substituted on carbon or nitrogen by 1, 2 or 3 halo or C_{1-4}alkyl groups~~; **$R^{1'}$** is a group selected from–$COR^{8'}$, -$CONR^{8'}R^9$ and C_{1-6}alkyl which C_{1-6}alkyl is substituted by hydroxy and optionally further substituted by 1 or 2 halo or methoxy groups; **$R^{2'}$** is a group selected from hydrogen, -COR^{10}, –$CONR^{10}R^{11}$ and C_{1-6}alkyl which C_{1-6}alkyl is optionally substituted by 1, 2 or 3 halo or C_{1-4}alkoxy groups, –$S(O)_pR^{11}$ (where p is 0, 1 or 2) or hydroxy, or $R^{2'}$ is a group selected from C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-6}cycloalkyl and C_{3-6}cycloalkylC_{1-4}alkyl; ~~or **$R^{1'}$** and **$R^{2'}$** together with the nitrogen to which they are attached form a 4- to 7- membered ring optionally containing a further nitrogen atom which ring may be saturated, unsaturated or partially saturated and which ring is substituted on carbon or nitrogen by a group selected from hydroxy and C_{1-4}alkyl which C_{1-4}alkyl is substituted by hydroxy or –$NR^{8'}R^9$ and which ring is optionally further substituted on carbon or nitrogen by 1, 2 or 3 halo or C_{1-4}alkyl groups;~~ and where **$R^{8'}$** is C_{1-4}alkyl substituted by hydroxy and optionally further substituted by 1 or 2 halo or methoxy groups:

and thereafter if necessary:

i) converting a compound of the formula (I) into another compound of the formula (I); and/or

ii) removing any protecting groups; and/or

iii) forming a pharmaceutically acceptable salt thereof.

19. (withdrawn) The method according to claim 16 wherein Aurora kinase is Aurora-A kinase or Aurora-B kinase.

20. (currently amended) A compound according to claim 1 wherein **A** is a group of formula (b) ~~or (d)~~:



(b)

where * is the point of attachment to the X group of formula (I) and ** is the point of attachment to the Y group of formula (I);

X is NH;

m is 0, 1, 2, 3 or 4;

Y is a group selected from O, NR^5CO, $CONR^5$, $CR^6R^7CONR^5$ and $CR^6R^7NR^5$;

Z is a group selected from $-NR^1R^2$~~, phosphonooxy, C_{3-6}cycloalkyl which C_{3-6}cycloalkyl is substituted by phosphonooxy or C_{1-4}alkyl substituted by phosphonooxy, and a 4- to 7-membered ring linked via a carbon atom containing a nitrogen atom and optionally containing a further nitrogen atom, which ring may be saturated, unsaturated or partially saturated which ring is substituted on carbon or nitrogen by phosphonooxy or C_{1-4}alkyl (substituted by phosphonooxy) and which ring is optionally further substituted on carbon or nitrogen by 1, 2 or 3 halo or C_{1-4}alkyl groups~~;

R^1 is a group selected from $-COR^8$, $-CONR^8R^9$ and C_{1-6}alkyl which C_{1-6}alkyl is substituted by phosphonooxy and optionally further substituted by 1 or 2 halo or methoxy groups;

R^2 is a group selected from hydrogen, $-COR^{10}$, $-CONR^{10}R^{11}$ and C_{1-6}alkyl which C_{1-6}alkyl is optionally substituted by 1, 2 or 3 halo or C_{1-4}alkoxy groups, $-S(O)_pR^{11}$ (where p is 0, 1 or 2) or phosphonooxy, or R^2 is a group selected from C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-6}cycloalkyl and C_{3-6}cycloalkylC_{1-4}alkyl;

~~or **R^1** and **R^2** together with the nitrogen to which they are attached form a 4- to 7- membered ring optionally containing a further nitrogen atom which ring may be saturated, unsaturated or partially saturated which ring is substituted on carbon or nitrogen by a group selected from phosphonooxy and C_{1-4}alkyl substituted by phosphonooxy or $-NR^8R^9$, and which ring is optionally further substituted on carbon or nitrogen by 1, 2 or 3 halo or C_{1-4}alkyl groups;~~

R^3 is a group selected from hydrogen, halo, cyano, nitro, C_{1-6}alkoxy, C_{1-6}alkyl, $-OR^{12}$, $-CHR^{12}R^{13}$, $-OC(O)R^{12}$, $-C(O)R^{12}$, $-NR^{12}C(O)R^{13}$, $-C(O)NR^{12}R^{13}$, $-NR^{12}SO_2R^{13}$ and $-NR^{12}R^{13}$;

R^4 is phenyl or benzyl optionally substituted by 1 or 2 of fluoro or chloro;

R^5 is a group selected from hydrogen, C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, C_{3-6}cycloalkyl and C_{3-6}cycloalkylC_{1-4}alkyl;

R^6 and **R^7** are independently selected from hydrogen, halo, C_{1-4}alkyl, C_{3-6}cycloalkyl, hydroxy and C_{1-4}alkoxy;

R^8 is C_{1-4}alkyl substituted by phosphonooxy and optionally further substituted by 1 or 2 halo or methoxy groups;

R^9 is selected from hydrogen and C_{1-4}alkyl;

R^{10} is selected from hydrogen and C_{1-4}alkyl which C_{1-4}alkyl is optionally substituted by halo, C_{1-4}alkoxy, $S(O)_q$ (where q is 0, 1 or 2) or phosphonooxy;

R^{11}, **R^{12}** and **R^{13}** are independently selected from hydrogen, C_{1-4}alkyl and heterocyclyl;

or a pharmaceutically acceptable salt thereof.

21. (Currently amended) A compound according to claim 1, wherein:

A is a group of formula (a)~~, (b), (c) or (d)~~ or (b):



(a) (b)

where * is the point of attachment to the X group of formula (I) and ** is the point of attachment to the Y group of formula (I);

X is NH;

m is 0, 1, 2, 3 or 4;

Y is O, NR^5CO or $CR^6R^7NR^5$

Z is $-NR^1R^2$~~, phosphonooxy, cyclopropyl which cyclopropyl is substituted by C_{1-4}alkyl substituted by phosphonooxy, and a piperidine or piperazine ring linked via a carbon atom which ring is substituted on carbon or nitrogen by phosphonooxy or C_{1-4}alkyl substituted by phosphonooxy;~~

~~**R^4** is C_{1-5}alkyl substituted by phosphonooxy~~;

R^2 is a group selected from hydrogen, C_{1-6}alkyl which C_{1-6}alkyl is optionally substituted by 1, 2 or 3 halo or C_{1-4}alkoxy groups, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-6}cycloalkyl and C_{3-6}cycloalkylC_{1-4}alkyl;

R^3 is C_{1-4}alkoxy or hydrogen;

R^4 is phenyl or benzyl optionally substituted by 1 or 2 of fluoro or chloro;

R^5 is hydrogen or methyl; and

R^6 and **R^7** are independently hydrogen, fluoro, chloro or methyl;

or a pharmaceutically acceptable salt thereof.

22. (cancelled)

23. (previously presented) A pharmaceutical composition comprising a compound according to claim 10 or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable diluent or carrier.